**NEED**
- Top tier Pharma company required 24-hour analysis turnaround for multi-site patient ascending dose study from sample receipt to Quality Controlled (QC’d) bioanalytical data
- Missing the timing window would result in delays to dosing in patient population
- Delays may have complicated the goal of correlating safety, effect and pharmacokinetic data as soon as possible

**APPROACH**
- Coordinated with the courier company to understand the expected arrival time for the samples anticipated from three continents
- Ensured that Celerion sample management was prepared to receive and batch the samples as soon as they arrived
- Ensured that the internal team understood that samples could arrive during the week or on Fridays and the mission would remain 24-hour analysis
- Ensured that the personnel who validated the method cross-trained with other key scientists to minimize the possibility of batch failure
- Ensured that the Celerion pharmacokineticist understood that the data may become available over the weekend or evening hours

**BENEFITS**
- The client was able to meet all internal expectations for their ascending dose study
- Concentration-effect correlations were understood as soon as possible, thus protecting the well-being of the patients

**See Other Case Studies**
- Mass Balance Study
- Partnering with Biotechnology Companies
- EU Biotech Needs First-in-Human FDA Support